Where Chinese Investors Meet Global Investment News and Opportunities


Generon Announces SPA for US Phase III Trial of Neutropenia Drug

Generon, a Shanghai innovative biopharma, has forged a Special Protocol Assessment with the US FDA for the design of a second Phase III trial of its lead candidate. Gereron believes F-627 (benegrastim), a second-generation recombinant human granulocyte colony-stimulating factor dimer, has best-in-class potential to treat chemotherapy-induced neutropenia. The company is also testing a first-in-class recombinant human interleukin-22 as a treatment for graft-vs-host disease and acute alcoholic hepatitis.

Source: China Biotoday

Do NOT follow this link or you will be banned from the site!